C40B50/00

De novo synthesized gene libraries

De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.

De novo synthesized gene libraries

De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.

ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

PEPTIDE LIBRARY AND USE THEREOF

Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.

NUCLEIC ACID MUTAGENESIS METHODS
20200181666 · 2020-06-11 · ·

The present disclosure relates to the manipulation of nucleic acids, and more particularly to systems and methods for nucleic acid mutagenesis.

NUCLEIC ACID MUTAGENESIS METHODS
20200181666 · 2020-06-11 · ·

The present disclosure relates to the manipulation of nucleic acids, and more particularly to systems and methods for nucleic acid mutagenesis.

DETERMINATION OF CANCER TYPE IN A SUBJECT BY PROBABILISTIC MODELING OF CIRCULATING NUCLEIC ACID FRAGMENT ENDPOINTS
20200157620 · 2020-05-21 ·

Method for diagnosis of one or more physiological conditions with probabilistic methods using cfDNAs are disclosed.

DETERMINATION OF CANCER TYPE IN A SUBJECT BY PROBABILISTIC MODELING OF CIRCULATING NUCLEIC ACID FRAGMENT ENDPOINTS
20200157620 · 2020-05-21 ·

Method for diagnosis of one or more physiological conditions with probabilistic methods using cfDNAs are disclosed.

DE NOVO SYNTHESIZED GENE LIBRARIES

De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.

LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.